Pfizer’s Centres for Therapeutic Innovation and the Jeffrey Modell Foundation team up to advance immunological research
Posted: 8 July 2015 | Victoria White
Pfizer’s Centres for Therapeutic Innovation and the Jeffrey Modell Foundation are to collaborate to conduct research in the field of immunological diseases…
Pfizer’s Centres for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced today a collaboration agreement to conduct research in the field of immunological diseases.
CTI and JMF will identify and co-fund translational research projects with leading academic medical centres within the CTI network. The goal of each research project will be to identify and validate a potential drug candidate for an immunological disease that can be moved into further clinical testing.
Immunological research collaboration represents JMF’s first alliance with a biopharmaceutical company
“Accelerating drug discovery is the goal of every CTI collaboration and this agreement aligns with two of our core therapeutic areas, immunology and rare diseases, where we have leading expertise and a long history in research and bringing treatments to patients,” said Anthony J. Coyle, senior vice president and CTI’s chief scientific officer. “With a deeply committed partner like the Jeffrey Modell Foundation, we have an opportunity to leverage our respective expertise to help enhance our understanding of the complex immune system, which plays a key role in many rare diseases.”
The collaboration with CTI represents JMF’s first alliance with a biopharmaceutical company. “We are excited about the opportunity to collaborate with Pfizer as we broaden our commitment to make a world of difference in the lives of patients with immunological diseases,” said Vicki Modell, co-founder of the Jeffrey Modell Foundation. “JMF’s expertise in Primary Immunodeficiency and extensive network of collaborators, combined with Pfizer’s impressive research and development capabilities has the potential to identify and advance novel research projects. Together, we hope to make meaningful advancements in our understanding of immunological diseases.”